Long-term overall survival from a phase I trial using intratumoral plasmid interleukin-12 with electroporation in patients with melanoma
2015
Background In 2007, a phase 1 dose-escalation safety study of intratumoral electroporation (EP) of plasmid interleukin-12 (pIL-12) was completed in 24 patients (pts) with malignant melanoma. IL-12 is thought to promote interferon-gpathway activation and antigen presentation and processing machinery (APM) to enhance systemic anti-tumor response. This phase 1 study was the first ever gene therapy in humans to use EP to locally deliver DNA plasmid to induce systemic anti-tumor immunity. Here we present long-term overall survival (OS) results from this study.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
5
Citations
NaN
KQI